Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors.
Market Cap | 55.432 Million | Shares Outstanding | 43.306 Million | Avg 30-day Volume | 723.336 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.31 |
Price to Revenue | 1026.069 | Debt to Equity | 0.0 | EBITDA | -18.901 Million |
Price to Book Value | 2.9303 | Operating Margin | -5214.7541 | Enterprise Value | 244.561 Million |
Current Ratio | 21.794 | EPS Growth | 0.614 | Quick Ratio | 21.458 |
1 Yr BETA | 1.8489 | 52-week High/Low | 8.58 / 1.13 | Profit Margin | -5275.1366 |
Operating Cash Flow Growth | -22.9697 | Altman Z-Score | 32.5573 | Free Cash Flow to Firm | -13.421 Million |
Earnings Report | 2022-08-04 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
89,574 | 2022-03-09 | 3 | |
|
125,317 | 2022-03-09 | 2 | |
|
89,574 | 2022-03-09 | 2 | |
|
124,627 | 2022-03-09 | 2 | |
LEVINE JAMES E. CHIEF FINANCIAL OFFICER |
|
560,016 | 2022-03-09 | 4 |
|
70,801 | 2022-03-09 | 3 | |
|
89,574 | 2022-03-09 | 2 | |
ERLANDER MARK CHIEF EXECUTIVE OFFICER |
|
1,185,400 | 2022-03-09 | 2 |
|
70,801 | 2022-03-09 | 3 | |
KELEMEN VICKI EXEC. VP AND COO |
|
572,784 | 2022-03-09 | 2 |
RUFFNER KATHERINE L CHIEF MEDICAL OFFICER |
|
370,016 | 2022-03-09 | 3 |
SMEAL TOD CHIEF SCIENTIFIC OFFICER |
|
0 | 2022-01-10 | 1 |
|
3,345,090 | 2021-06-10 | 1 | |
|
608,848 | 2021-06-10 | 1 | |
|
3,290,000 | 2020-09-30 | 0 | |
|
0 | 2019-06-20 | 0 | |
|
28,839 | 2018-06-08 | 0 | |
WELCH WILLIAM J CHIEF EXECUTIVE OFFICER |
|
842,645 | 2018-01-30 | 0 |
|
0 | 2018-01-23 | 0 | |
|
No longer subject to file | 2016-11-11 | 0 | |
ZANIBONI STEVE FORMER CFO |
|
96,968 | 2016-04-21 | 0 |
SCHUH ANTONIUS CEO |
|
0 | 2016-01-04 | 0 |
POSARD MATTHEW L. CHIEF COMMERCIAL OFFICER |
|
0 | 2016-01-04 | 0 |
|
0 | 2015-03-17 | 0 | |
|
0 | 2013-07-26 | 0 | |
|
0 | 2013-02-14 | 0 | |
|
9,065,004 | 2012-04-13 | 0 | |
SHEINERMAN KIRA |
|
1,363,636 | 2008-06-12 | 0 |
|
0 | 2008-01-03 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 22:15:03 UTC | 0.2382 | 0.5818 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 21:45:03 UTC | 0.2448 | 0.5752 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 21:15:03 UTC | 0.2448 | 0.5752 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 20:45:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 20:15:05 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 19:45:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 19:15:04 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 18:45:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 18:15:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 17:45:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 17:15:03 UTC | 0.2471 | 0.5729 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 16:45:04 UTC | 0.2329 | 0.5871 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 16:15:03 UTC | 0.2329 | 0.5871 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 15:45:03 UTC | 0.2329 | 0.5871 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 15:15:03 UTC | 0.2329 | 0.5871 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 14:45:03 UTC | 0.0287 | 0.7913 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 14:15:04 UTC | 0.0287 | 0.7913 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 13:45:03 UTC | 0.0287 | 0.7913 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 13:15:03 UTC | 0.0287 | 0.7913 | 1400000 |
CARDIFF ONCOLOGY INC CRDF | 2022-05-20 12:45:03 UTC | 0.0287 | 0.7913 | 1400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|